High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 475-483

  Xu, Yan ^a   Shi, Qun Li ^a   Ma, Henghui ^a   Zhou, Hangbo ^a   Lu, Zhenfeng ^a   Yu, Bo ^a   Zhou, Xiaojun ^a   Eriksson, Staffan ^b   He, Ellen ^b,c   Skog, Sven ^b,c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c Sino Swed Molecular Bio Medicine Research Institute   (China)

Author keywords

Immunohistochemistry; Lung adenocarcinoma; Stromal invasion; Survival; Thymidine kinase 1

Indexed keywords

ANTINEOPLASTIC AGENT; THYMIDINE KINASE 1; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; RETROSPECTIVE STUDY; STROMA; TUMOR VOLUME; ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; THYMIDINE KINASE;

EID: 84860311708     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0276-0     Document Type: Article

References (37)

1. Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996;201:798-802.
2. Sone S, Takashima S, Li F, Yang Z, Honda T, Maruyama Y, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998;351:1242-5.
3. Kawakami T, Nabeshima K, Makimoto Y, Hamasaki M, Iwasaki A, Shirakusa T, et al. Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors. Mod Pathol. 2007;20:514-21.
4. Suzuki K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Nagai K, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000;69:893-7.
5. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognosis factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29:179-88.
6. Maeshima AM, Niki T, Maeshima A, Yamada T, Kondo H, Matsuno Y. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer. 2002;95:2546-54.
7. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2006;26:4753-9.
8. Nisman B, Allweis T, Kaduri L, Maly B, Gronowitz S, Hamburger T, et al. Cancer biomark. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010;7:65-72.
9. He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleos Nucleot Nucleic Acids. 2010;29:352-8.
10. Li HX, Zhang S, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005;13:145-9.
11. Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010;76:513-6.
12. Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010;19:313-8.
13. Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010;15:359-68.
14. Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapytreated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol. 2010;136:1193-9.
15. Konoplev SN, Fritsche HA, O'Brien S, Wierda WG, Keating MJ, Gornet TG, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol. 2010;134:472-7.
16. Xu W, Cao X, Miao KR, Qiao C, Wu YJ, Liu Q, et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol. 2009;90:205-11.
17. Holdenrieder S, Von Pawel J, Duell T, Feldmann K, Raith H, Schollen A, et al. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Res. 2010;30:1855-62.
18. Broet P, Romain S, Daver A, Ricolleau G, Quillen V, Rallet A, et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol. 2001;19:2778-87.
19. Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, et al. Thymidine kinase 1 expression is significantly different in breast benign (UDH), and in pre-malignant (ADH), primary tumour in situ (DCIS) and invasive ductal (IDC) of breast carcinoma. Mol Med Report. 2009;2:923-9.
20. Sakurai H, Maeshima A, Watanabe S, Suzuki K, Tsuchiya R, Maeshima AM, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28:198-206.
21. Sakao Y, Miyamoto H, Sakuraba M, Oh T, Shiomi K, Sonobe S, et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg. 2007;83:209-83214.
22. Sakao Y, Sakuragi T, Natsuaki M, Itoh T. Clinicopathological analysis of prognostic factors in clinical IA peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2003;75:1113-7.
23. Yamashiro K, Yasuda S, Nagase A, Hirata T, Nojima T, Nagashima K. Prognostic significance of an interface pattern of central fibrosis and tumor cells in peripheral adenocarcinoma of the lung. Hum Pathol. 1995;26:67-73.
24. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937-51.
25. Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007;20:233-41.
26. Xu Y, Zhou XJ, Ma HH, Lu ZF, He Y. Prognostic significance of stromal invasion grade and micropapillary pattern in early-stage adenocarcinoma of the lung. J Clin Exp Pathol. 2009;25:498-502.
27. Sobin LH, Gospodarowicz MK, Wittekind CH, International Union Against Cancer (UICC). TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2009. p. 138-46.
28. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization Classification of tumours. Pathology and genetics: tumours of lung, pleura, thymus and heart. Lyon: IARC; 2004. p. 68-77.
29. Brockenbrough JS, Morihara JK, Hawes SE, Stern JE, Rasey JS, Wiens LW, et al. Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem. 2009;57:1087-97.
30. Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem. 2010;28:27327-35.
31. Topolcan O, Lubos Holubec L. The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn. 2008;2:129-40.
32. Mao Y, Wu J, Wang N, He L, Wu C, He Q, et al. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest. 2002;20:922-31.
33. He Q, Mao Y, Wu J, Decker C, Merza M, Wang N, et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol. 2004;25:945-53.
34. Wu J, Mao Y, He L, Wang N, Wu C, He Q, et al. A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res. 2000;20:4815-20.
35. Mao Y, Wu J, Skog S, Eriksson S, Zhao Y, Zhou J, et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep. 2005;13:837-46.
36. Gakis G, Hennenlotter J, Scharpf M, Hevler J, Schilling D, Kuehs U, et al. (2011) XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J Urol (in press).
37. Zhao H, Albino AP, Jorgensen E, Traganos F, Darzynkiewicz Z. DNA damage response induced by tobacco smoke in normal human bronchial epithelial and A549 pulmonary adenocarcinoma cells assessed by laser scanning cytometry. Cytometry A. 2009;75:840-7.